55
https://pubmed.ncbi.nlm.nih.gov/38094526
This study suggests that in patients with Clostridioides difficile infection, fidaxomicin treatment had worse outcomes due to restricted usage, potentially impacting its effectiveness, particularly for severe or recurrent cases.